高血压与非酒精性脂肪性肝病的关系

王欣; 胡义扬; 刘平; 冯琴

doi:10.3969/j.issn.1001-5256.2020.11.042

高血压与非酒精性脂肪性肝病的关系

DOI: 10.3969/j.issn.1001-5256.2020.11.042

1. 上海中医药大学附属曙光医院
2. 上海市中医临床重点实验室
3. 肝肾疾病病证教育部重点实验室

基金项目:

国家自然基金重点项目（81830119）；国家科技重大专项“重大新药创制”项目（2019ZX09201001-001-002）；

详细信息

中图分类号: R575.5;R544.1
计量
- 文章访问数: 664
- HTML全文浏览量: 44
- PDF下载量: 140
- 被引次数: 0
出版历程
- 收稿日期: 2020-04-28
- 出版日期: 2020-11-20

Association between hypertension and nonalcoholic fatty liver disease

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine
Shanghai Key Laboratory of Traditional Chinese Clinical Medicine
Key Laboratory of Liver and Kidney Diseases,Ministry of Education

Research funding:

摘要

摘要:
非酒精性脂肪性肝病（NAFLD）与高血压同为代谢综合征的重要组成部分,二者之间有很强的关联性。通过临床数据分析了NAFLD与高血压之间的联系。简述了二者之间相互影响的共同可能机制。其中,胰岛素抵抗、肠道菌群、肾素-血管紧张素-醛固酮系统在二者的发病机制中起着重要的作用。同时也总结了肾素-血管紧张素-醛固酮系统抑制药以及利尿剂在NAFLD治疗中的应用,为今后进一步明确二者之间的关系,深入了解二者相互影响的机制以及NAFLD合并高血压的治疗提供参考。
- 非酒精性脂肪性肝病 /
- 高血压 /
- 治疗学
Abstract:
Nonalcoholic fatty liver disease( NAFLD) and hypertension are both important components of metabolic syndrome,and there is a strong association between these two diseases. This article analyzes the association between NAFLD and hypertension based on clinical data and describes the common pathogeneses of the two diseases,among which insulin resistance,gut microbiota,renin-angiotensin-aldosterone system play an important role in the pathogenesis of these two diseases. In addition,this article briefly summarizes the application of renin-angiotensin-aldosterone system inhibitors and diuretics in the treatment of NAFLD,which provides a reference for further clarifying the association between these two diseases,understanding the mechanism of interaction between the two diseases,and exploring the treatment methods for NAFLD with hypertension.
- non-alcoholic fatty liver disease /
- hypertension /
- therapeutics

HTML全文

参考文献(40)

[1]ZHOU J,ZHOU F,WANG W,et al.Epidemiological feature of NAFLD from 1999 to 2018 in China[J].Hepatology,2020,75(5):1851-1864.

[2]ZHOU F,ZHOU J,WANG W,et al.Unexpected rapid increase in the burden of NAFLD in China from 2008 to 2018:A systematic review and meta-analysis[J].Hepatology,2019,70(4):1119-1133.

[3]LONARDO A,NASCIMBENI F,MANTOVANI A,et al.Hypertension,diabetes,atherosclerosis and NASH:Cause or consequence?[J].J Hepatol,2018,68(2):335-352.

[4]MILLS KT,STEFANESCU A,HE J.The global epidemiology of hypertension[J].Nat Rev Nephrol,2020,16(4):223-237.

[5]LOPEZ-SUAREZ A,GUERRERO JM,ELVIRA-GONZALEZ J,et al.Nonalcoholic fatty liver disease is associated with blood pressure in hypertensive and nonhypertensive individuals from the general population with normal levels of alanine aminotransferase[J].Eur J Gastroenterol Hepatol,2011,23(11):1011-1017.

[6]LORBEER R,BAYERL C,AUWETER S,et al.Association between MRI-derived hepatic fat fraction and blood pressure in participants without history of cardiovascular disease[J].J Hypertens,2017,35(4):737-744.

[7]ANENT EC,ONI ET,MARTIN SS,et al.Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of card iometabolic risk[J].J Hypertens,2015,33(6):1207-1214.

[8]FENG RN,DU SS,WANG C,et al.Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population[J].World J Gastroenterol,2014,20(47):17932-17940.

[9]BONNET F,GASTALDELLI A,PIHAN-LE BARS F,et al.Gamma-glutamyltransferase,fatty liver index and hepatic insulin resistance are associated with incident hypertension in two longitudinal studies[J].J Hypertens,2017,35(3):493-500.

[10]HUH JH,AHN SV,KOH SB,et al.A prospective study of fatty liver index and incident hypertension:The KoGESARIRANG study[J].PLoS One,2015,10(11):e0143560.

[11]RYOO JH,SUH YJ,SHIN HC,et al.Clinical association between non-alcoholic fatty liver disease and the development of hypertension[J].J Gastroenterol Hepatol,2014,29(11):1926-1931.

[12]SUNG KC,WILD SH,BYRNE CD.Development of new fattyliver,or resolution of existing fatty liver,over five years of follow-up,and risk of incident hypertension[J].J Hepatol,2014,60(5):1040-1045.

[13]QIAN LY,TU JF,DING YH,et al.Association of blood pressure level with nonalcoholic fatty liver disease in nonhypertensive population:Normal is not the new normal[J].Medicine(Baltimore),2016,95(29):e4293.

[14]WANG Y,ZENG Y,LIN C,et al.Hypertension and non-alcoholic fatty liver disease proven by transient elastography[J].Hepatol Res,2016,46(13):1304-1310.

[15]MA J,HWANG SJ,PEDLEY A,et al.Bi-directional analysis between fatty liver and cardiovascular disease risk factors[J].J Hepatol,2017,66(2):390-397.

[16]SORRENTINO P,TERRACCIANO L,D'ANGELO S,et al.Predicting fibrosis worsening in obese patients with NASH through parenchymal fibronectin,HOMA-IR,and hypertension[J].Am J Gastroenterol,2010,105(2):336-344.

[17] SINGH S,ALLEN AM,WANG Z,et al.Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis:A systematic review and meta-analysis of paired-biopsy studies[J].Clin Gastroenterol Hepatol,2015,13(4):643-654.

[18] European Association for the Study of the Liver(EASL);European Association for the Study of Diabetes(EASD);European Association for the Study of Obesity(EASO).EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease[J].J Hepatol,2016,64(6):1388-1402.

[19]NAKAMURA M,YAMAZAKI O,SHIRAI A,et al.Preserved Na/HCO3 cotransporter sensitivity to insulin may promote hypertension in metabolic syndrome[J].Kidney Int,2015,87(3):535-542.

[20]ALAM S,MUSTAFA G,ALAM M,et al.Insulin resistance in development and progression of nonalcoholic fatty liver disease[J].World J Gastrointest Pathophysiol,2016,7(2):211-217.

[21]KHAN RS,BRIL F,CUSI K,et al.Modulation of insulin resistance in nonalcoholic fatty liver disease[J].Hepatology,2019,70(2):711-724.

[22]BOLLER S,JOBLIN BA,XU L,et al.From signal transduction to signal interpretation:An alternative model for the molecular function of insulin receptor substrates[J].Arch Physiol Biochem,2012,118(3):148-155.

[23]GUO S.Insulin signaling,resistance,and the metabolic syndrome:Insights from mouse models into disease mechanisms[J].J Endocrinol,2014,220(2):T1-T23.

[24]HORITA S,SEKI G,YAMADA H,et al.Insulin resistance,obesity,hypertension,and renal sodium transport[J].Int J Hypertens,2011,2011:391762.

[25]ARTUNC F,SCHLEICHER E,WEIGERT C,et al.The impact of insulin resistance on the kidney and vasculature[J].Nat Rev Nephrol,2016,12(12):721-737.

[26]MINEMURA M,SHIMIZU Y.Gut microbiota and liver diseases[J].World J Gastroenterol,2015,21(6):1691-1702.

[27]JI Y,YIN Y,LI Z,et al.Gut microbiota-derived components and metabolites in the progression of non-alcoholic fatty liver disease(NAFLD)[J].Nutrients,2019,11(8):1712.

[28]MARQUES FZ,MACKAY CR,KAYE DM.Beyond gut feelings:How the gut microbiota regulates blood pressure[J].Nat Rev Cardiol,2018,15(1):20-32.

[29]LEUNG C,RIVERA L,FURNESS JB,et al.The role of the gutmicrobiota in NAFLD[J].Nat Rev Gastroenterol Hepatol,2016,13(7):412-425.

[30]KANG Y,CAI Y.Gut microbiota and hypertension:From pathogenesis to new therapeutic strategies[J].Clin Res Hepatol Gastroenterol,2018,42(2):110-117.

[31]TE RIET L,van ESCH JH,ROKS AJ,et al.Hypertension:Renin-angiotensin-aldosterone system alterations[J].Circ Res,2015,116(6):960-975.

[32]PASCHOS P,TZIOMALOS K.Nonalcoholic fatty liver disease and the renin-angiotensin system:Implications for treatment[J].World J Hepatol,2012,4(12):327-331.

[33]MATTHEW MORRIS E,FLETCHER JA,THYFAULT JP,et al.The role of angiotensin II in nonalcoholic steatohepatitis[J].Mol Cell Endocrinol,2013,378(1-2):29-40.

[34]WU Y,MA KL,ZHANG Y,et al.Lipid disorder and intrahepatic renin-angiotensin system activation synergistically contribute to non-alcoholic fatty liver disease[J].Liver Int,2016,36(10):1525-1534.

[35]TOBLLI JE,MUNOZ MC,CAO G,et al.ACE inhibition and AT1receptor blockade prevent fatty liver and fibrosis in obese Zucker rats[J].Obesity(Silver Spring),2008,16(4):770-776.

[36]POLYZOS SA,KOUNTOURAS J,MANTZOROS CS,et al.Effects of combined low-dose spironolactone plus vitamin E vs vitamin E monotherapy on insulin resistance,non-invasive indices of steatosis and fibrosis,and adipokine levels in non-alcoholic fatty liver disease:A randomized controlled trial[J].Diabetes Obes Metab,2017,19(12):1805-1809.

[37]YOKOHAMA S,YONEDA M,HANEDA M,et al.Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis[J].Hepatology,2004,40(5):1222-1225.

[38]GEORGESCU EF,IONESCU R,NICULESCU M,et al.Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis[J].World J Gastroenterol,2009,15(8):942-954.

[39]MILIC S,MIKOLASEVIC I,KRZNARIC-ZRNIC I,et al.Nonalcoholic steatohepatitis:emerging targeted therapies to optimize treatment options[J].Drug Des Devel Ther,2015,9:4835-4845.

[40]MCPHERSON S,WILKINSON N,TINIAKOS D,et al.A randomised controlled trial of losartan as an anti-fibrotic agent in non-alcoholic steatohepatitis[J].PLoS One,2017,12(4):e0175717.

施引文献

资源附件(0)

访问统计